FierceBiotech1d
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...
STAT1d
Metsera’s GLP-1 drug has potential for monthly dosing, new data show
Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi ...
BioSpace1d
New Weight Loss Biotech Metsera Stuns with 7.5% Weight Loss, Few Side Effects
Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...
The Valdosta Daily Times1d
Metsera Reports Highly Competitive Results from Ongoing Trial of Novel, Potential Once-Monthly Injectable GLP-1 Receptor Agonist MET-097
Metsera plans to initiate a Phase 2b trial of MET-097 in Q4 2024, with data anticipated in the first half of 2025.
ENDPOINTS NEWS1d
Clive Mean­well's new obe­si­ty biotech, Met­sera, un­veils ear­ly GLP-1 da­ta with an eye on Phase 3 next year
Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...
Why Weight-Loss Drugs Are Billion-Dollar Blockbusters: QuickTake
Obesity is among the world’s most common health conditions, but for years medicine had few effective approaches to offer ...